查詢結果分析
相關文獻
- 2016年NCCN準則之大腸癌新藥
- 大腸直腸癌篩檢簡介
- Irinotecan (Campto[feb9])--治療大腸直腸癌的新藥
- 大腸直腸癌的流行病學特徵及可能之成因
- 大腸直腸癌症病患生活品質及其相關因素之探討
- Colonoscopic Surveillance in Asymptomatic Persons with Family History of Colorectal Cancer
- 大腸直腸癌術後肺臟轉移之手術治療
- 大腸直腸癌化學治療之近況
- The Operative Management of Small Bowel Obstruction in Patients with Previously Treated Colorectal Carcinoma
- Relationship between Size of Colorectal Cancer and Treatment: A Comparative Study
頁籤選單縮合
題名 | 2016年NCCN準則之大腸癌新藥=New Antineoplastic Agents in 2016 NCCN Guideline of Colon Cancer |
---|---|
作者 | 陳弘益; | 書刊名 | 藥學雜誌 |
卷期 | 32:4=129 2016.12[民105.12] |
頁次 | 頁67-70 |
分類號 | 418.31 |
關鍵詞 | 大腸直腸癌治療藥物; 大腸直腸癌; 免疫治療藥品; Trifluridine; Tipiracil; Ramucirumab; Colorectal cancer; Chemotherapy; Target therapy; |
語文 | 中文(Chinese) |
中文摘要 | 大腸直腸癌治療藥物近年來不斷有進展,早期合併使用5-fluororuracil 及 oxaliplatin 或 irinotecan 使得存活率增加,而標靶治療藥物,像是血管內皮細胞生 長因子抑制劑 bevacizumab (Avastin)、aflibercept (Zaltrap, 柔癌捕),及上皮生長因子 受體抑制劑-cetuximab (Erbitux)、panitumumab (Vectibix),多重標靶酪胺酸激酶抑 制劑 regorafenib,提供病人更多的治療機會。2016年美國國家癌症資訊網 (National Comprehensive Cancer Network, NCCN) 準則新增大腸直腸癌新藥 trifluridine/tipiracil (Lonsurf) 和 ramucirumab (Cyramza),trifluridine/tipiracil 用於已經用過其他治療藥品的 轉移性大腸直腸癌病人,ramucirumab 則是與 FOLFIRI 併用,治療已經用過其他治療 第一線藥品,像是 fluoropyrimidine、bevacizumab、oxaliplatin 的轉移性大腸直腸癌病 人,免疫治療藥品像是 pembrolizumab 在台灣有針對轉移性大腸直腸癌病人的臨床試 驗仍在進行中。 |
英文摘要 | In recent years, there is a continuous progress in the treatment of colorectal cancer. In earlier period, combination therapy of 5-fluororuracil and oxaliplatin or irinotecan increased survival rate of colorectal cancer patient. Targeted therapy such as vascular endothelial growth factor (bevacizumab, aflibercept), epidermal growth factor receptor (cetuximab, panitumumab) and multi-kinase inhibitor (regorafenib) provide more opportunities for these patients. In 2016, the National Comprehensive Cancer Network (NCCN) published new guideline which contains two new antineoplastic agents, trifluridine/tipiracil (Lonsurf) and ramucirumab (Cyramza). Trifluridine/tipiracil is used to treat adults with metastatic colorectal cancer who have already been treated with, or who cannot be given, other available treatments.Ramucirumab is used in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- and fluoropyrimidine-containing regimen. On the other hand, immunotherapy agent such as pembrolizumab is still in clinical trial in Taiwan. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。